Blogs

A pharmaceutical package doesn't need a visible crack to put product quality at risk. Microscopic leak paths, often undetectable through visual inspection alone, can create pathways for moisture, gases, or contaminants to enter a package. Depending on the product and packaging system, these defects may compromise stability, sterility assurance, and shelf-life performance.

Understanding the relationship between package integrity and product stability is essential to developing a scientifically justified testing strategy. Deterministic Container Closure Integrity Testing (CCIT) provides objective data to help manufacturers evaluate package performance and identify potential integrity risks throughout the product lifecycle.

What Is the Connection Between Container Closure Integrity and Product Stability?

First, a stability program doesn't necessarily track sterility in the same way it tracks potency or purity. Stability studies evaluate appropriate quality attributes over time, while container closure integrity can provide supporting evidence for the continued maintenance of the sterile barrier.

Second, the statement about FDA guidance needs more precise attribution. FDA has recognized validated container closure integrity testing as an alternative to sterility testing at stability time points in appropriate circumstances. That does not mean every stability program must include CCIT at every time point.

Third, CCI data does not independently confirm that a package maintains its protective barrier throughout its entire shelf life.

How Can Microscopic Leak Paths Expose Products to Environmental Risks?

A leak path doesn't need to be large to matter. Pinholes in glass or plastic walls, micro-cracks, and irregularities where a stopper, crimp, or cap doesn't maintain full sealing contact can all open a pathway that's active for the entire time a product sits in storage or transit.

What gets through that pathway depends on the product, but the risks generally fall into a few categories:

• Microbial ingress: Potential pathways for microbial contamination that may compromise the sterile barrier.
• Oxygen ingress: Exposure that may contribute to oxidative degradation in oxygen-sensitive formulations.
• Moisture ingress: Exposure that may affect moisture-sensitive formulations, including certain lyophilized products.

Because these pathways can develop or worsen after a product passes release testing, a package that was sealed correctly at manufacture isn't guaranteed to stay that way through the rest of its shelf life.

How Does VeriPac Vacuum Decay Detect and Quantify Package Leaks Non-Destructively?

Vacuum Decay is an established deterministic leak detection method that evaluates package integrity by monitoring pressure changes within a controlled test chamber. PTI's VeriPac technology provides objective, quantitative measurement data to help identify package leaks without requiring destructive testing.

VeriPac systems can be configured to evaluate a variety of pharmaceutical packaging formats, including vials, prefilled syringes, bottles, blister packages, and flexible packaging, depending on the application.

Test sensitivity and performance are established through appropriate method development and validation using representative package configurations and known defects.

Because Vacuum Decay is non-destructive, it can support package development, laboratory quality testing, stability studies, and automated production inspection where appropriate.

The resulting data helps manufacturers evaluate package integrity, compare test results, and make informed quality decisions.

How Can Deterministic CCIT Identify Package Integrity Risks Throughout Development and Stability Programs?

A deterministic result does more than tell you a package passed or failed. It gives you a specific, repeatable number that can be compared across materials, designs, and production settings, which is exactly what's needed to catch a risk early rather than after it reaches a patient.

Integrating deterministic CCIT into appropriate stages of the product lifecycle provides valuable data on package performance. These results can help manufacturers identify potential integrity risks, investigate changes in package performance, and support decisions related to package design, process control, and stability.

What's the Key Takeaway on Small Defects and Product Stability?

A defect too small to see is not too small to matter. Microscopic leak paths can create pathways for moisture, oxygen, or contaminants to enter pharmaceutical packaging, potentially affecting product quality and stability.

Container Closure Integrity Testing provides objective evidence to help manufacturers understand package performance and identify potential risks throughout the product lifecycle.

Deterministic, non-destructive technologies such as PTI's VeriPac Vacuum Decay support a science-based approach to package integrity evaluation—from initial package development through stability studies and commercial manufacturing.

By integrating appropriate CCIT methods into their quality and stability strategies, manufacturers can strengthen confidence in packaging performance and support informed product quality decisions.

Frequently Asked Questions

1. Is VeriPac Vacuum Decay testing destructive to the product or package?

No. Testing is non-destructive and non-invasive, so the product and package remain usable and can be retested if needed.

2. Can Vacuum Decay testing be used during package development, not just in production?

Yes. Because it produces quantitative, comparable data, it's commonly used in R&D and tooling qualification to compare packaging materials and designs before a product ever reaches production.

3. What industry standards and guidance support Vacuum Decay testing?

Vacuum Decay is described in ASTM F2338, a standardized test method for non-destructive leak detection in packaging. It is also recognized among the deterministic leak testing approaches discussed in USP <1207>. PTI's VeriPac technology can support package integrity testing programs developed and validated in alignment with applicable industry standards and regulatory expectations.

A sterile drug product doesn't just need to stay free of microorganisms. For many formulations, it also needs to stay free of oxygen. Package integrity testing is how manufacturers confirm that the seal protecting a sterile product from microbial contamination is the same seal keeping oxygen out, for the entire time that product carries a shelf-life claim.

Why Can Oxygen Exposure Affect Sensitive Sterile Drug Products?

Oxidation is one of the most common degradation pathways in pharmaceutical formulations. Proteins and peptides are particularly vulnerable, since oxygen can alter sensitive amino acid residues and change a molecule's structure in ways that reduce its biological activity.

This isn't only a release-day concern. Oxidative damage tends to build gradually:

• Trace oxygen in a package's headspace can react with the product from the moment it's filled
• Oxygen permeating slowly through a compromised seal adds to that exposure over months or years
• The cumulative effect can show up as reduced potency, visible discoloration, or impurities well before the labeled expiration date

Because the damage accumulates over time, a package only has to hold up for a moment at release. It has to hold up for the product's entire shelf life.

How Can Package Defects Create Pathways for Oxygen Ingress?

A package defect doesn't need to be large to matter. A pinhole or micro-crack measured in single-digit microns is invisible to the eye, but it still gives oxygen a continuous pathway into the headspace over the course of a shelf life.

Common sources of oxygen ingress include:

• Pinholes or micro-cracks in glass or plastic container walls
• Gaps where a stopper or plunger doesn't maintain full sealing contact
• Irregularities in a crimp or cap seal introduced during assembly
• Seal delamination or channel leaks in flexible pouches and blister formats

These same defects threaten sterility, which is exactly why a single, quantitative test method that detects physical breaches is so valuable: it addresses both risks at once, rather than treating oxygen protection and sterility as separate problems.

How Does PTI Vacuum Decay Identify Leaks That May Compromise Package Protection?

It's worth noting what Vacuum Decay technology actually measures. It doesn't test oxygen concentration directly. It detects whether a physical leak pathway exists at all, which is the more fundamental question: if there's no leak path, oxygen, moisture, and microorganisms cannot get in regardless of how long the product sits in storage.

The test itself is straightforward and fast. A package goes into a specially designed chamber, vacuum is applied, and single or dual vacuum transducers monitor the chamber for any change in vacuum level over a set test time. A change beyond expected limits indicates a defect.

What Role Does CCIT Play in Supporting Product Stability and Quality?

A pass or fail result alone doesn't tell a quality team much about risk. Quantitative CCITdata does, because it ties a specific defect size to a specific level of risk, which is exactly the kind of evidence a stability program and a regulatory submission are built around.

That data supports product stability and quality in several concrete ways:

• It replaces subjective, probabilistic inspection with objective, reproducible measurements
• It can be built into QA/QC statistical process control, catching defects before they reach a patient
• It gives quality teams a defensible basis for batch release and root-cause investigations when a failure does occur

For oxygen-sensitive sterile products specifically, that assurance means a manufacturer isn't just hoping the package holds. They have the data to show it does, for as long as the shelf-life claim says it should.

What's the Key Takeaway for Oxygen-Sensitive Sterile Products?

Protecting an oxygen-sensitive sterile product means protecting the seal around it, since the same defect that lets in a microorganism can just as easily let in oxygen. Vacuum decay testing addresses that risk directly by detecting the physical leak paths that would otherwise go unnoticed, and the quantitative data it produces gives manufacturers a defensible way to support both sterility and oxidative stability for a product's entire shelf life.

Frequently Asked Questions

1. Does vacuum decay testing measure oxygen levels inside the package?

No. Vacuum decay detects whether a physical leak path exists by monitoring pressure change in a test chamber. If no leak path is present, oxygen cannot enter the package regardless of external oxygen levels.

2. Can vacuum decay testing be used on flexible packaging like pouches?

Yes. PTI's VeriPac systems are validated for rigid, semi-rigid, and flexible packaging made from porous or non-porous materials, including pouches and blister formats.

3. How small a leak can PTI's Vacuum Decay technology detect?

Standard VeriPac systems detect leaks in the single-digit micron range, and the VeriPac Delta extends sensitivity further with vacuum decay down to 5 microns and pressure decay down to 10 microns.

Pharmaceutical products face a range of environmental stressors during their journey from manufacturing to the patient, but moisture is one of the most damaging and hardest to detect. A package can look perfectly intact, pass a visual inspection, and still carry a defect small enough to let water vapor through over weeks or months of storage and transport. By the time the effect shows up as reduced potency, a failed dissolution test, or visible caking, the product has often already left the manufacturing site.

This is why package integrity has become a defined, testable requirement rather than an assumption built into packaging design. Understanding how moisture actually gets in, and how that ingress can be reliably detected before it becomes a quality failure, is central to protecting both patients and manufacturers. This article looks at why moisture control matters so much for sensitive formulations, how microscopic defects form and let moisture through, how vacuum decay technology detects those defects, and how routine Package integrity testing protects product quality and shelf life over the long term.

Why Is Moisture Control Critical for Moisture-Sensitive Pharmaceutical Products?

Hygroscopic APIs are common across solid oral dosage forms, lyophilized biologics, and effervescent products, and each reacts differently to moisture exposure depending on its chemical structure and formulation. Uncontrolled moisture ingress can trigger hydrolysis, reduce potency, alter dissolution rates, and create conditions for microbial growth, all before a product reaches the patient. Even small, gradual moisture uptake over a product's shelf life can be enough to push a batch outside its approved specifications.

Common consequences of moisture exposure include:

• Chemical degradation: hydrolysis reactions that reduce API potency over time
• Physical changes: caking, clumping, or softening of tablets and powders
• Altered dissolution: changes to how quickly a drug releases in the body
• Microbial risk: elevated moisture can support unwanted microbial growth

Because the degree of risk varies by formulation, packaging engineers cannot rely on assumptions. Every packaging system needs to be verified against its actual barrier performance, not just its intended design.

How Can Microscopic Package Defects Allow Moisture Ingress?

These defects can form at any stage of the packaging lifecycle, from the initial molding or forming of the container, through sealing and filling, to distribution and storage. Because moisture can migrate through openings far smaller than the human eye can resolve, a package that looks and feels intact can still be compromised. These defects typically originate from:

• Seal inconsistencies: incomplete heat seals or contamination trapped in the seal area
• Micro cracks: caused by thermal cycling, transport vibration, or handling stress
• Cap and liner defects: improper torque or liner misalignment on vials and bottles
• Material flaws: pinholes or thin spots introduced during molding or forming

Because these defects are often invisible to the naked eye and inconsistent from unit to unit, visual inspection alone cannot reliably catch them. This is precisely why quantitative, instrument based testing has become essential across pharmaceutical, biotech, and medical device packaging lines.

How Does Vacuum Decay Technology Detect Package Leaks?

This approach is deterministic rather than probabilistic, meaning the result is based on a direct physical measurement rather than a visual or subjective judgment call. PTI's VeriPac systems apply single or dual vacuum transducer technology, with PERMA-VAC design further increasing the signal to noise ratio between good and defective samples for more consistent detection, down to the single digit micron range. The method works across rigid, semi-rigid, and flexible packaging, including vials, syringes, blister packs, pouches, and IV bags, making it broadly applicable across a manufacturer's full product portfolio.

Because vacuum decay is non destructive, it can be used on one hundred percent of production, in process samples, or stability samples, without sacrificing product.

How Does Package Integrity Testing Protect Product Quality and Shelf Life?

Package integrity testing protects product quality and shelf life by confirming, with objective data, that a package will maintain its barrier properties for as long as the product needs it to.

Rather than relying on end of shelf life stability data alone, manufacturers can use routine CCIT to catch packaging problems early, often before a single unit reaches distribution. This supports:

• Regulatory compliance: alignment with ASTM F2338, USP <1207>, and ISO 11607
• Batch release confidence: quantitative pass or fail criteria instead of subjective judgment
• Shelf life validation: evidence to support stability study conclusions
• Reduced recall risk: catching defects before product reaches the market or a patient

For manufacturers of moisture sensitive pharmaceuticals, routine CCIT is not just a quality checkbox. It is a direct safeguard against the chemical and physical degradation that moisture ingress can cause, and a documented line of defense during regulatory audits.

Frequently Asked Questions

1. What is CCIT?

Container closure integrity testing (CCIT) is the practice of verifying that a packaging system maintains a reliable barrier against contamination, including moisture and microorganisms, throughout its intended shelf life.

2. Is vacuum decay testing destructive?

No. Vacuum decay is a non-destructive method. The tested package and its contents remain usable and can proceed through the supply chain after testing.

3. What is the smallest leak vacuum decay technology can detect?

PTI's vacuum decay systems, including the VeriPac Delta, can detect leaks in the single digit micron range, depending on package specifications and materials.

4. How often should package integrity testing be performed?

Testing frequency depends on regulatory requirements, product risk, and packaging type, but many manufacturers incorporate CCIT into in process checks, batch release testing, and ongoing stability studies.

5. Does vacuum decay work on flexible packaging as well as rigid containers?

Yes. Vacuum decay technology is compatible with rigid, semi-rigid, and flexible packaging formats, including pouches and IV bags, as well as both porous and non-porous materials.